Author

A. Do

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

A. Acker· 1 shared A. N. Hata· 1 shared A. Shiba-Ishii· 1 shared B. Y. Yeap· 1 shared E. Borgeson· 1 shared E. Esteve· 1 shared F. Sheikh· 1 shared I. Dagogo-Jack· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Acker

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Combined loss of obscurin and obscurin-like 1 in murine hearts results in diastolic dysfunction, altered metabolism and deregulated mitophagy.

K. Fujita, P. Desmond, J. Blondelle, M. Sotak, M. R. Rajan, M. Clark, E. Esteve, Y. Chan, Y. Gu, V. Marrocco, N. D. Dalton, M. Ghassemian, A. Do, M. Klos, K. L. Peterson, , S. Lange

This study shows that loss of obscurin and Obsl1 in mice causes diastolic dysfunction, altered metabolism, and deregulated mitophagy in the heart.

bioRxiv · Aug 24, 2022 · PreprintCell Biology

Structural and functional analysis of lorlatinib analogs reveals roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

A. Shiba-Ishii, T. W. Johnson, I. Dagogo-Jack, M. Mino-Kenudson, T. R. Johnson, P. Wei, S. L. Weinrich, M. A. McTigue, M. A. Walcott, L. Nguyen-Phuong, K. Dionne, A. Acker, L. Kiedrowski, A. Do, J. L. Peterson, , A. N. Hata

This study identifies lorlatinib-resistant ALK mutations and evaluates analogs to develop targeted therapies for compound resistance in ALK-positive lung cancer.

Nature Cancer · Jun 20, 2022Peer-reviewedCancer Biology